Clinical TrialJul 27, 2026, 08:11 AM
Veru Completes Enrollment in Phase 2b PLATEAU Clinical Trial
AI Summary
Veru Inc. announced the completion of enrollment in its Phase 2b PLATEAU clinical study for enobosarm, which exceeded the targeted 200 patients. The trial evaluates the effect of oral enobosarm 3 mg versus placebo in older patients with obesity who are initiating semaglutide treatment. Interim analysis results are anticipated in the first quarter of 2027, with final topline data expected in the fourth quarter of 2027.
Key Highlights
- Completed enrollment in Phase 2b PLATEAU clinical trial with ~200 patients.
- Interim analysis results for the study are expected in Q1 2027.
- Final topline clinical data is expected in Q4 2027.
- The trial evaluates enobosarm 3 mg versus placebo in older patients (age ≥ 65) with obesity (BMI ≥ 35) initiating semaglutide.
- Enobosarm aims to maximize fat loss while preserving lean mass, physical function, and bone mineral density.
Price Impact
More from VERU